Siemens announces two companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen. ViiV Healthcare, a global specialist HIV company, delivers advances in treatment and care for people living with HIV. Tocagen is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development, and commercialization of gene transfer products for the treatment of cancer.
According to the World Health Organization, 33.3 million people worldwide were living with HIV as of 2009. That same year, 2.6 million new infections were reported and 1.8 million people worldwide died of AIDS-related illnesses. Siemens’ partnership with ViiV Healthcare will focus on clinical trials related to Selzentry (maraviroc)—ViiV Healthcare’s novel CCR5 co-receptor antagonist for the treatment of CCR5-tropic HIV—leveraging the CLIA accredited Siemens Clinical Laboratory, as well as Siemens’ establisheThe Siemens–Tocagen relationship will begin with diagnostic tests to support clinical trials related to Tocagen’s unique viral gene therapy (Toca 511 & Toca FC) under investigation for the treatment of primary brain cancer, followed by potential commercialization of diagnostic tests for therapy monitoringd in vitro diagnostics (IVD) clinical and regulatory expertise.
Addressing real needs
ViiV Healthcare previously announced the start of the Phase III MODERN Study, also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients infected with CCR5-tropic HIV-1. In addition, MODERN is the first large Phase III trial that will compare the performance of a genotypic test with a phenotypic test in identifying patients appropriate for use of Celsentri/Selzentry®.
“Our partnership with Siemens is a valuable part of our commitment to addressing patient needs through developing innovative treatment approaches,” said John Pottage, MD, Chief Scientific and Medical Officer, ViiV Healthcare. “Celsentri/Selzentry is an important treatment option for people living with CCR5-tropic HIV and we continue to support the evolution of tropism testing to provide physicians with accurate, accessible, and affordable companion diagnostics”.